←
ReCode Therapeutics171 posts
ReCode Therapeutics avatar

ReCode Therapeutics

@ReCodeTx

ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics.

◷ Joined October 2020▧ 135 Photos and videos
ReCode Therapeutics avatar
ReCode Therapeutics@ReCodeTx·11 Nov 2022

Better delivery platforms can unleash the true potential of genetic medicines. These must deliver drugs beyond the liver – to the lungs, spleen, and beyond. Learn how we are powering the next wave of genetic medicines through superior delivery: recodetx.com/

Post attachment
ReCode Therapeutics avatar
ReCode Therapeutics@ReCodeTx·1 Nov 2022

We’re excited to attend #NACFC2022 this year with other members of the #CysticFibrosis community. Please visit us at booth #1020 to learn more about our investigational therapy for CF patients who have nonsense mutations & do not respond to currently approved CFTR modulators.

Post attachment
ReCode Therapeutics avatar
ReCode Therapeutics@ReCodeTx·28 Oct 2022

We’re very proud to have been nominated for the 2022 #PrixGalien award for “Best Startup in the Pharmaceutical or Biotechnology Industry.” Thank you @GalienFdn for this honor and congratulations to all of this year’s winners and nominees for your work to improve human health!

Post attachment
ReCode Therapeutics avatar
ReCode Therapeutics@ReCodeTx·20 Oct 2022

Will we see you at #PODD2022 in Boston next week? On Monday, our director of BD Ariel Kantor will talk about how our novel SORT LNP platform is overcoming the limitations of conventional LNPs to enable superior delivery of #RNA and next-gen gene correction therapeutics

Post attachment
ReCode Therapeutics avatar
ReCode Therapeutics@ReCodeTx·19 Oct 2022

Moreover, our SORT LNP platform can deliver optimized, functional CFTR mRNA as an aerosol to the intended secretory and basal cells.

ReCode Therapeutics avatar
ReCode Therapeutics@ReCodeTx·19 Oct 2022

Second, we’re developing a next-generation LNP delivery technology to target organs like the lungs with genetic medicines such as CFTR mRNA.

ReCode Therapeutics avatar
ReCode Therapeutics@ReCodeTx·19 Oct 2022

First, we’re developing an investigational mRNA therapy for CF that focuses specifically on the 10 to 13 percent of CF patients who have nonsense mutations and do not respond to currently approved CFTR modulators.